Improved rating elevates Hikma to global leadership
position
LONDON, Jan. 13, 2021 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma, Group), the multinational
generic pharmaceutical company, has received an 'A-' rating from
the CDP 2020 Global Climate Change Report, improving on the Group's
previous score and elevating Hikma to CDP's Leadership Band of
companies implementing current best practices.
CDP is an independent, not-for-profit organisation aimed at
enabling companies to progress towards environmental stewardship
through benchmarking and comparison with peers.
In the 2020 report, Hikma received an "A" rating in five
separate categories ranked by CDP, including for its emission
reduction initiatives, its scope 1 and 2 emissions (greenhouse gas
emissions from direct fuel usage and electricity consumption), its
governance and risk management processes, and its business strategy
and financial planning. Hikma's performance – with at or above
average marks in every category evaluated – exceeded the global
average, the European regional average, and the biotech and pharma
sector average.
"As a company, we have worked hard to continually improve our
environmental performance and we are proud to see those focused
efforts recognised with a strong rating from the CDP that places us
in a leadership position among global companies," explained
Hana Ramadan, Vice President of
Corporate Social Responsibility at Hikma. "In line with our mission
to help put better health within reach, every day, we are committed
to further reducing our climate impact and improving the resilience
of our business in the face of future climate change. We will
continue working collaboratively across the Group to improve the
efficiency and sustainability of our operations, products and
services."
In 2020, Hikma began aligning its climate change management with
the Task-Force on Climate-Related Financial Disclosures (TCFD), a
set of voluntary, consistent disclosure recommendations established
with input from a wide range of industries and countries for use by
companies in providing information to investors, lenders and
insurance underwriters about their climate-related financial risks.
The Group also continued to drive energy efficiency and renewable
energy in its manufacturing operations, approving plans to increase
solar power generation at its manufacturing site in Sintra,
Portugal in 2021.
To learn more about the sustainability work at Hikma, please
visit https://www.hikma.com/sustainability/.
Enquiries
Hikma Pharmaceuticals
PLC
Brooke Clarke,
Communications and Corporate Affairs
|
+44 (0)20 7399 2795/
+44 7970338250
media@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable
Moody's)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our unique insight and
expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,600
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
Logo -
https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.jpg